Introgen aims for first gene therapy approval in US and EU with cancer therapy
This article was originally published in Scrip
Executive Summary
Introgen Therapeutics has filed for US and EU approval for its novel gene therapy drug Advexin to treat recurrent, refractory head and neck cancer. If approved, it could become the first gene therapy product for any disease in both regions.